Structure

InChI Key AQIXAKUUQRKLND-UHFFFAOYSA-N
Smile CN/C(=N/CCSCc1nc[nH]c1C)NC#N
InChI
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H16N6S
Molecular Weight 252.35
AlogP 0.6
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 5.0
Polar Surface Area 88.89
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 17.0

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Histamine H2 receptor antagonist ISBN
Primary Target
H2 receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Gastrointestinal Hemorrhage 3 D006471 ClinicalTrials
Dermatitis, Atopic 3 D003876 ClinicalTrials
Ulcer 3 D014456 ClinicalTrials
Hemorrhage 3 D006470 ClinicalTrials
Breast Carcinoma In Situ 2 D000071960 ClinicalTrials
Endometrial Neoplasms 2 D016889 ClinicalTrials
Amyotrophic Lateral Sclerosis 1 D000690 ClinicalTrials
Pulmonary Disease, Chronic Obstructive 1 D029424 ClinicalTrials
Anxiety Disorders 1 D001008 ClinicalTrials

Related Entries

Salt

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Cardiac disorders
13.94
General disorders and administration site conditions
13.51
Gastrointestinal disorders
10.55
Psychiatric disorders
9.23
Nervous system disorders
8.99
Investigations
7.91
Injury, poisoning and procedural complications
6.87
Respiratory, thoracic and mediastinal disorders
4.47
Metabolism and nutrition disorders
3.77
Vascular disorders
3.53
Immune system disorders
3.48
Skin and subcutaneous tissue disorders
3.44

Cross References

Resources Reference
CAS NUMBER 51481-61-9
ChEBI 3699
ChEMBL CHEMBL30
DrugBank DB00501
DrugCentral 645
EPA CompTox DTXSID4020329
FDA SRS 80061L1WGD
Human Metabolome Database HMDB0014644
Guide to Pharmacology 1231
KEGG C06952
PharmGKB PA449001
PubChem 2756
SureChEMBL SCHEMBL1093
ZINC ZINC000018115268